WO2003014145A3 - Peptides that bind to atherosclerotic lesions - Google Patents

Peptides that bind to atherosclerotic lesions Download PDF

Info

Publication number
WO2003014145A3
WO2003014145A3 PCT/EP2002/008942 EP0208942W WO03014145A3 WO 2003014145 A3 WO2003014145 A3 WO 2003014145A3 EP 0208942 W EP0208942 W EP 0208942W WO 03014145 A3 WO03014145 A3 WO 03014145A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerotic lesions
peptides
methods
bind
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/008942
Other languages
French (fr)
Other versions
WO2003014145A2 (en
Inventor
Cheng Liu
Thomas S Edgington
Margaret Forney Prescott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Scripps Research Institute
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG, Scripps Research Institute filed Critical Novartis Pharma GmbH Austria
Priority to US10/486,318 priority Critical patent/US20070264194A1/en
Priority to CA002455336A priority patent/CA2455336A1/en
Priority to EP02772136A priority patent/EP1419173B1/en
Priority to JP2003519094A priority patent/JP2005507244A/en
Priority to AU2002336959A priority patent/AU2002336959B2/en
Priority to DE60230046T priority patent/DE60230046D1/en
Publication of WO2003014145A2 publication Critical patent/WO2003014145A2/en
Publication of WO2003014145A3 publication Critical patent/WO2003014145A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides peptides that selectively bind to mammalian atherosclerotic lesions. The present invention also provides methods for in vivo identification of peptides capable of binding to biomolecules as well as methods for identifying the targets of such binding moieties. Methods to diagnose or treat pathologic conditions that involve atherosclerotic lesions are also provided by the invention that involve administering to a mammal a peptide attached to a reporter molecule or a therapeutic agent, respectively.
PCT/EP2002/008942 2001-08-10 2002-08-09 Peptides that bind to atherosclerotic lesions Ceased WO2003014145A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/486,318 US20070264194A1 (en) 2001-08-10 2002-08-09 Peptides That Bind To Atherosclerotic Lesions
CA002455336A CA2455336A1 (en) 2001-08-10 2002-08-09 Peptides that bind to atherosclerotic lesions
EP02772136A EP1419173B1 (en) 2001-08-10 2002-08-09 Peptides that bind to atherosclerotic lesions
JP2003519094A JP2005507244A (en) 2001-08-10 2002-08-09 Peptides that bind to atherosclerotic lesions
AU2002336959A AU2002336959B2 (en) 2001-08-10 2002-08-09 Peptides that bind to atherosclerotic lesions
DE60230046T DE60230046D1 (en) 2001-08-10 2002-08-09 PEPTIDES BINDING ATHEROSCLEROTIC INJURIES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31150701P 2001-08-10 2001-08-10
US60/311,507 2001-08-10

Publications (2)

Publication Number Publication Date
WO2003014145A2 WO2003014145A2 (en) 2003-02-20
WO2003014145A3 true WO2003014145A3 (en) 2003-12-04

Family

ID=23207200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008942 Ceased WO2003014145A2 (en) 2001-08-10 2002-08-09 Peptides that bind to atherosclerotic lesions

Country Status (8)

Country Link
US (1) US20070264194A1 (en)
EP (1) EP1419173B1 (en)
JP (2) JP2005507244A (en)
AT (1) ATE415412T1 (en)
AU (1) AU2002336959B2 (en)
CA (1) CA2455336A1 (en)
DE (1) DE60230046D1 (en)
WO (1) WO2003014145A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528109B2 (en) 2007-10-26 2016-12-27 Biomarin Technologies B.V. Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
ATE462451T1 (en) 2004-06-16 2010-04-15 Affinergy Inc INTERFACE BIOMATERIALS TO PROMOTE ADHESION OF TARGET ANALYTES
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1940841B9 (en) 2005-10-07 2017-04-19 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US7531505B2 (en) 2006-01-11 2009-05-12 Affinergy, Inc. Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
AU2007282224B2 (en) 2006-08-11 2013-08-29 Vico Therapeutics B.V. Methods and means for treating DNA repeat instability associated genetic disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
FR2942227B1 (en) 2009-02-13 2011-04-15 Guerbet Sa USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION
CA2759899A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
WO2011065968A1 (en) * 2009-11-30 2011-06-03 The Scripps Research Institute Use of monocyte chemoattractant compounds to treat ocular disorders
FR2968999B1 (en) 2010-12-20 2013-01-04 Guerbet Sa CHELATE NANOEMULSION FOR MRI
FR2980364B1 (en) 2011-09-26 2018-08-31 Guerbet NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS
CN112251436A (en) 2012-01-27 2021-01-22 比奥马林技术公司 RNA-regulated oligonucleotides with improved properties for the treatment of duchenne muscular dystrophy and becker muscular dystrophy
HK1210953A1 (en) 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
FR3001154B1 (en) 2013-01-23 2015-06-26 Guerbet Sa MAGNETO-EMULSION VECTORIZED
EP2886140A1 (en) * 2013-12-17 2015-06-24 University of Limerick An apparatus for the extracorporeal treatment of blood
JP7365050B2 (en) * 2018-02-14 2023-10-19 達也 沢村 Fusion protein and high-density lipoprotein measurement kit using the same
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
US20220378943A1 (en) * 2019-11-15 2022-12-01 Osaka University Enhancer polynucleotide responding to heart failure and expression vector including said enhancer polynucleotide
CN117820429B (en) * 2024-01-11 2024-06-18 中国水产科学研究院南海水产研究所 Snakehead source active peptide with INOS inhibition effect

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580550A1 (en) * 1992-07-21 1994-01-26 Ciba-Geigy Ag Oxamic acid derivatives as hypocholesteremic agents
WO1994013327A1 (en) * 1992-12-15 1994-06-23 The Wellcome Foundation Limited Immunoreactive reagents employing dihydrofolate reductase
WO1994029333A1 (en) * 1993-06-07 1994-12-22 The Wellcome Foundation Limited Immunoreactive reagents employing monoamine oxidase
US5827516A (en) * 1992-08-11 1998-10-27 President And Fellows Of Harvard College Immunomodulatory peptides
WO2000051971A1 (en) * 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
WO2001032853A1 (en) * 1999-10-29 2001-05-10 Institute For Applied Biomedicine B cell clonal toxins and methods for using the same
WO2002094854A2 (en) * 2001-05-21 2002-11-28 The Brigham And Women's Hospital, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
WO2001057252A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580550A1 (en) * 1992-07-21 1994-01-26 Ciba-Geigy Ag Oxamic acid derivatives as hypocholesteremic agents
US5827516A (en) * 1992-08-11 1998-10-27 President And Fellows Of Harvard College Immunomodulatory peptides
WO1994013327A1 (en) * 1992-12-15 1994-06-23 The Wellcome Foundation Limited Immunoreactive reagents employing dihydrofolate reductase
WO1994029333A1 (en) * 1993-06-07 1994-12-22 The Wellcome Foundation Limited Immunoreactive reagents employing monoamine oxidase
WO2000051971A1 (en) * 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
WO2001032853A1 (en) * 1999-10-29 2001-05-10 Institute For Applied Biomedicine B cell clonal toxins and methods for using the same
WO2002094854A2 (en) * 2001-05-21 2002-11-28 The Brigham And Women's Hospital, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FAVRE ET AL.: "STRUCTURAL MIMICRY OF CANONICAL CONFORMATIONS IN ANTIBODY HYPERVARIABLE LOOPS USING CYCLIC PEPTIDES CONTAINING A HETEROCHIRAL DIPROLINE TEMPLATE", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 121, no. 12, 31 March 1999 (1999-03-31), pages 2679 - 2685, XP002137023, ISSN: 0002-7863 *
FRANK, RONALD: "Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support", TETRAHEDRON, vol. 48, no. 42, 16 October 1992 (1992-10-16), Oxford, GB, ISSN: 0040-4020, pages 9217 - 9232, XP000353580 *
LUU T N ET AL: "Calcitonin gene-related peptide in healthy and atheromatous human epicardial coronary arteries: Function and receptor characterization.", JOURNAL OF VASCULAR RESEARCH, vol. 32, no. 2, 1995, pages 93 - 99, XP009010613, ISSN: 1018-1172 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528109B2 (en) 2007-10-26 2016-12-27 Biomarin Technologies B.V. Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
US11478535B2 (en) 2016-12-15 2022-10-25 Talengen International Limited Method for preventing and treating fatty liver
US11547746B2 (en) 2016-12-15 2023-01-10 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof

Also Published As

Publication number Publication date
WO2003014145A2 (en) 2003-02-20
DE60230046D1 (en) 2009-01-08
ATE415412T1 (en) 2008-12-15
US20070264194A1 (en) 2007-11-15
JP2009050275A (en) 2009-03-12
CA2455336A1 (en) 2003-02-20
AU2002336959B2 (en) 2006-07-13
EP1419173A2 (en) 2004-05-19
JP2005507244A (en) 2005-03-17
EP1419173B1 (en) 2008-11-26

Similar Documents

Publication Publication Date Title
WO2003014145A3 (en) Peptides that bind to atherosclerotic lesions
WO2001055355A8 (en) Nucleic acids, proteins, and antibodies
WO2001055317A8 (en) Nucleic acids, proteins, and antibodies
WO2001055306A3 (en) Nucleic acids, proteins, and antibodies
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2001072958A3 (en) Bladder cancer-specific peptides for diagnosis and therapy
WO2001055300A8 (en) Nucleic acids, proteins, and antibodies
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055313A3 (en) Nucleic acids, proteins, and antibodies
WO2007020405A3 (en) Integrin i-domain binding peptides
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
GB2415195A (en) Peptides of IRF-1
WO2001055305A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HU ID IL IN IS JP KE KG KP KR KZ LK LT LU LV MA MD MK MN MX NO OM PH PL PT RO RU SE SG SI SK TJ TN TR TT UA US UZ VC VN YU ZA

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI GB GR IE IT LU MC NL PT SE SK TR

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002336959

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002772136

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2455336

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003519094

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002772136

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10486318

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10486318

Country of ref document: US